Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with resistant/refractory ovarian cancer

被引：0
|
作者：
Smit, W. M.
Sufliarsky, J.
Spanik, S.
Wagnerova, M.
Kaye, S.
Oza, A. M.
Gore, M.
Williams, K. J.
Johri, A.
Huinink, W. W. ten Bokkel
机构：
[1] Med Spectrum Twente, Enschede, Netherlands
[2] Natl Canc Inst, Bratislava, Slovakia
[3] St Elisabeth Canc Inst, Bratislava, Slovakia
[4] Inst Oncol, Kosice, Slovakia
[5] Royal Marsden Hosp, Sutton, Surrey, England
[6] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[7] Novartis Pharma AG, Basel, Switzerland
[8] Novartis Pharmaceut Corp, E Hanover, NJ USA
[9] Netherlands Canc Inst, Amsterdam, Netherlands
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：261 / 262
页数：2
相关论文
共 50 条
  • [1] Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer.
    Smit, WM
    Sufliarsky, J
    Spanik, S
    Wagnerová, M
    Kaye, S
    Oza, AM
    Gore, M
    Williams, K
    Johri, A
    Huinink, WWT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 468S - 468S
  • [2] Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer
    Sanchez, J. M.
    Osterlind, K.
    Zatloukal, P.
    Hamm, J.
    Belani, C. P.
    Kim, E.
    Felip, E.
    Berton, M.
    Sklenar, I.
    John, A.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 327 - 327
  • [3] Phase I/II dose-escalation trial of patupilone administered every 3 weeks (q 3 wk) in patients (pts) with relapsed/refractory ovarian, primary fallopian, or primary peritoneal cancer
    Smit, Willem M.
    Honkoop, Aafke H.
    Spanik, Stanistav
    Wagnerova, Maria
    Sufliarsky, Jozef
    Oza, Amit M.
    Kaye, Stan
    Pereno, Raffaele
    Sklenar, Ivo
    Huinink, W. W. ten B.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 127 - 127
  • [4] Phase I/II dose escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer.
    Osterlind, K
    Sánchez, JM
    Zatloukal, P
    Hamm, J
    Belani, CP
    Kim, E
    Felip, E
    Johri, A
    Berton, M
    Sklenar, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 647S - 647S
  • [5] A phase I/II dose-escalation trial of EP0906 every 3 weeks in patients with relapsed/refractory ovarian, primary fallopian, or primary peritoneal cancer.
    Smit, WM
    Honkoop, AH
    Spanik, S
    Wagnerova, M
    Huinink, WWTB
    Oza, AM
    Kaye, SB
    Mull, R
    Pereno, R
    Sklenar, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 474S - 474S
  • [6] A phase I/II dose-escalation trial of patupilone (EPO906) administered every 3 weeks in patients with non-small cell lung cancer (NSCLC)
    Oesterlind, Kell
    Sanchez, Jose
    Zatloukal, Petr
    Perry, Michael
    Hamm, John
    Belani, Chandra
    Kim, Edward
    Vansteenkiste, Johan
    Felip, Enriqueta
    Berton, Myriam
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 167 - 167
  • [7] Phase I/II trial of patupilone once every 3 weeks in patients with non-small cell lung cancer (NSCLC)
    Osterlind, K
    Sánchez, J
    Zatloukai, P
    Hamm, J
    Belani, C
    Kim, E
    Felip, E
    Sklenar, I
    Berton, M
    Johri, A
    [J]. LUNG CANCER, 2005, 49 : S261 - S261
  • [8] Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer
    Alexandra Leary
    Christophe Le Tourneau
    Andrea Varga
    Marie-Paule Sablin
    Carlos Gomez-Roca
    Nicolas Guilbaud
    Aurelie Petain
    Mariya Pavlyuk
    Jean-Pierre Delord
    [J]. Investigational New Drugs, 2019, 37 : 693 - 701
  • [9] Phase I dose-escalation study of F14512, a polyamine-vectorized topoisomerase II inhibitor, in patients with platinum-refractory or resistant ovarian cancer
    Leary, Alexandra
    Le Tourneau, Christophe
    Varga, Andrea
    Sablin, Marie-Paule
    Gomez-Roca, Carlos
    Guilbaud, Nicolas
    Petain, Aurelie
    Pavlyuk, Mariya
    Delord, Jean-Pierre
    [J]. INVESTIGATIONAL NEW DRUGS, 2019, 37 (04) : 693 - 701
  • [10] A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer
    Ryan, CW
    Stadler, WM
    Vogelzang, NJ
    [J]. BJU INTERNATIONAL, 2005, 95 (07) : 963 - 968
12345